GeneDx Holdings (WGS) risk factors, FY2024 10-K

Risks Related to Our Business, Industry and Operations

1. 01We need to scale our infrastructure in advance of demand for our tests, and our failure to generate sufficient demand for our tests would have a negative impact on our business and our ability to attain profitability
2. 02If we are not able to continue to generate substantial demand for our tests, our commercial success will be negatively affected
3. 03If our laboratories become inoperable due to disasters, health epidemics or for any other reasons, we will be unable to perform tests and our business will be harmed
4. 04Other companies or institutions may develop and market novel or improved technologies, which may make our technologies less competitive or obsolete
5. 05We face intense competition. If we do not continue to innovate and provide products and services that are useful to customers, including providers and patients, and partners, we may not remain competitive, which could harm our business and operating results
6. 06We use artificial intelligence in our business, and challenges with properly managing its use could result in reputational harm, competitive harm, and legal liability, and adversely affect our results of operations
7. 07We have incurred net losses and negative cash flows from operations since our inception, with an accumulated deficit of $1.4 billion as of December 31, 2024
8. 08Our credit agreement contains operating and financial restrictions that may limit our business and financing activities
9. 09Ethical, legal and social concerns related to the use of genomic medicine and health information analysis could reduce demand for our tests
10. 10If we fail to comply with federal and state laboratory licensing requirements or standards, we could lose the ability to perform our tests or experience disruptions to our business
11. 11We would also be required to maintain in-state licenses if we were to conduct testing in other states. Several states require the licensure of out-of-state laboratories that accept specimens from certain states

Risks Related to Our Business Model

1. 12We rely on highly skilled personnel in a broad array of disciplines and, if we are unable to hire, retain or motivate these individuals, or maintain our corporate culture, we may not be able to maintain the quality of our services or grow effectively
2. 13The loss of any member or change in structure of our senior management team could adversely affect our business
3. 14We may not be able to manage our future growth effectively, which could make it difficult to execute our business strategy
4. 15International expansion of our business could expose us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the U.S
5. 16Unfavorable U.S. or global economic conditions could adversely affect our business, financial condition or results of operations
6. 17We have sourced and will continue to source components of our diagnostic testing workflow, including sequencers and other laboratory equipment, reagents, lab supplies and other laboratory services and materials and related services, from third parties
7. 18Our current and future products and services may never achieve significant commercial market acceptance
8. 19We have estimated the global market opportunity for our current and future products and services, and these markets may be smaller than we estimate
9. 20Uncertainty in the development and commercialization of our enhanced or new tests or services could materially adversely affect our business, financial condition and results of operations
10. 21These and other factors beyond our control could result in delays or other difficulties in the research and development, approval, production, launch, marketing or distribution of enhanced or new tests and could adversely affect our competitive position and results of operations
11. 22If our products and services do not perform as expected, we may not realize the expected benefits of such products and services
12. 23Our operating results could be subject to significant fluctuation, which could increase the volatility of our stock and warrant prices and cause losses to our stockholders
13. 24Our revenue growth rate could decline over time, and it may experience downward pressure on our operating margins in the future
14. 25Our ability to use our net operating loss carry forwards and certain other tax attributes may be limited

Risks Related to Our Key Relationships

1. 26We rely on commercial delivery services to transport samples to our facilities in a timely and cost-efficient manner and if these delivery services are disrupted, our business could be harmed

Risks Related to Acquisitions and Other Strategic Transactions

1. 27or technologies. Our potential inability to integrate any acquired products or technologies effectively may adversely affect our business, operating results and financial condition

Risks Related to Legal, Regulatory and Compliance

1. 28We may be subject to increased compliance risks as a result of our rapid growth, including our dependence on our sales, marketing and billing efforts
2. 29If we use hazardous materials in a manner that causes injury, we could be liable for resulting damages
3. 30Changes in FDA enforcement discretion for laboratory developed tests LDTs could subject our operations to much more significant regulatory requirements
4. 31Multiple lawsuits have been filed challenging the FDA’s authority to regulate LDTs as medical devices under the Federal Food, Drug, and Cosmetic Act. The outcome of these lawsuits is uncertain at this time
5. 32As a provider of clinical diagnostic products and services, we and our partners are subject to extensive and frequently changing federal, state, local and foreign laws and regulations governing various aspects of our business
6. 33cannot predict what additional changes, if any, will be proposed or adopted or the effect that such proposals or adoption may have on our business, financial condition and results of operations
7. 34Compliance with the HIPAA security, privacy and breach notification regulations may increase our costs
8. 35Some of our activities may subject the Company to risks under federal and state laws prohibiting ‘kickbacks’ and false or fraudulent claims
9. 36program, and payments may be recouped by CMS if it is determined that they were improperly made. Currently, a small percentage of our revenues are generated by payments from Medicare
10. 37We may never obtain approval in the EU or in any other foreign country for any of our products or services and, even if we do, we or our partners and collaborators may never be able to commercialize them in another jurisdiction, which would limit our ability to realize their full market potential
11. 38Complying with numerous statutes and regulations pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties
12. 39We face uncertainty related to healthcare reform, pricing, coverage and reimbursement, which could reduce our revenue
13. 40U.S. healthcare industry may result in decreased profits to us, which may adversely affect our business, financial condition and results of operations
14. 41Product and professional liability suits against us could result in expensive and time-consuming litigation, payment of substantial damages and increases in our insurance rates
15. 42Errors, defects, or mistakes in our products or services, and operations could harm our reputation, decrease market acceptance of our products or services
16. 43We are subject to increasingly complex taxation rules and practices, which may affect how we conduct our business and our results of operations

Risks Related to Our Intellectual Property

1. 44Our inability to effectively protect our proprietary products, processes, and technologies, could harm our competitive position
2. 45Any inability to effectively protect our proprietary technologies under certain jurisdictions and legal regimes could harm our competitive position
3. 46If patent regulations or standards are modified, such changes could have a negative impact on our business
4. 47If we are not able to adequately protect our trade secrets and other proprietary information, including the databases we manage and to which we have access, the value of our technology and products could be significantly diminished
5. 48If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest, and our business may be adversely affected
6. 49Litigation or other proceedings resulting from either third-party claims of patent infringement, or asserting infringement by third parties of our technology, could be costly, time-consuming, and could limit our ability to commercialize our products or services
7. 50Our use of open-source software could subject our business to possible litigation or cause us to subject our platform to unwanted open-source license conditions that could negatively impact our sales
8. 51We rely on strategic collaborative and licensing arrangements with third parties to develop intellectual property. We may not be able to successfully establish and maintain such intellectual property

Risks Related to Cybersecurity, Privacy and Information Technology

1. 52Interruption, interference with, or failure of our information technology and communications systems could hurt our ability to effectively provide our products and services, which could harm our reputation, financial condition, and operating results
2. 53Security breaches, privacy issues, loss of data and other incidents could continue to compromise sensitive, protected, or personal information related to our business, could prevent it from accessing critical information, and could expose it to regulatory liability, which could adversely affect our business
3. 54We depend on our scientific computing and information technology and management systems and any failure of these systems could harm our business
4. 55Our ability to transfer data stored outside of the U.S. could be limited by international regulations or other action by foreign governments, which could adversely affect our business

Risks Related to Being a Public Company

1. 56We incur significant costs and demands on management as a result of compliance with laws and regulations applicable to public companies, which could harm our operating results
2. 57A market for our securities may not continue, which would adversely affect the liquidity and price of our securities
3. 58If we do not meet the expectations of investors, stockholders or financial analysts, the market price of our securities may decline
4. 59If securities or industry analysts cease publishing research or reports about us, our business, or our market, or if they change their recommendations regarding our Class A common stock adversely, then the price and trading volume of our Class A common stock could decline
5. 60Changes in laws, regulations or rules, or a failure to comply with any laws, regulations or rules, may adversely affect our business, investments and results of operations
6. 61Anti-takeover provisions contained in our Charter and Bylaws, as well as provisions of Delaware law, could impair a takeover attempt
7. 62The JOBS Act permits “emerging growth companies” like us to take advantage of certain exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies
8. 63We no longer qualify as a “smaller reporting company” and as a result, we will no longer be able to avail ourselves of certain reduced reporting requirements applicable to smaller reporting companies starting with our first quarterly report in 2025
9. 64Our internal controls over financial reporting may not be effective which could have a significant and adverse effect on our business and reputation
10. 65The stockholders will not be deemed to have waived our compliance with the federal securities laws and the regulations promulgated thereunder

Risks Related to Our Common Stock and Warrants

1. 66The ownership of our outstanding Class A common stock is concentrated, with certain of our stockholders owning significant percentages of our outstanding shares
2. 67These stockholders may choose to dispose of some or all of the shares of our Class A common stock held by them. Any disposal of shares of Class A common stock by any of these stockholders, or the perception that these sales could occur, could cause the market price of our stock or warrants to decline
3. 68We may redeem unexpired public warrants prior to their exercise at a time that is disadvantageous to warrant holders, thereby making their public warrants worthless
4. 69Our warrants are exercisable for our Class A common stock, which will increase the number of shares eligible for future resale in the public market and result in dilution to our stockholders
5. 70Our warrants are accounted for as liabilities and the changes in value of our warrants could have a material effect on our financial results
6. 71Sales of a substantial number of shares of our Class A common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our Class A common stock
7. 72We cannot guarantee that we will be able to satisfy the continued listing standards of Nasdaq going forward and if we fail to satisfy the continued listing requirements of Nasdaq, including the minimum closing bid price requirement, Nasdaq may take steps to delist our Class A common stock